Impact of Intrapartum Oral Azithromycin on the Acquired Macrolide Resistome of Infants' Nasopharynx: A Randomized Controlled Trial
Abdoulie Bojang, Sarah L Baines, Bully Camara, Romain Guerillot, Liam Donovan, Raquel Sanchez Marques, Ousman Secka, Umberto D'Alessandro, Christian Bottomley, Benjamin P Howden, Anna Roca
Clinical Infectious Diseases | OXFORD UNIV PRESS INC | Published : 2020
In a post hoc analysis of samples from an intrapartum azithromycin randomized clinical trial, we found that children whose mothers had been treated with the drug had higher prevalence of macrolide-resistance genes msr(A) and ermC at 28 days but not at 12 months. The 2 genes were positively associated in the nasopharynx. CLINICAL TRIALS REGISTRATION: NCT1800942.
Awarded by UK Department for International Development (DFID)
This work was jointly supported by the Medical Research Council (MRC) Unit, The Gambia, at the London School of Hygiene and Tropical Medicine PhD fellowship awarded to A. B. The main trial was jointly funded by the UK MRC and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement (reference number MR/J010391/1) and is also part of the EDCTP2 program supported by the European Union.